Literature DB >> 17611963

Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus.

Adnan N Kiani1, James A Mahoney, Michelle Petri.   

Abstract

OBJECTIVE: To determine the association of serum asymmetric dimethylarginine (ADMA) with clinical features, laboratory tests, treatment, cardiovascular risk factors, and subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).
METHODS: Serum ADMA concentrations were determined by ELISA, using purified ADMA as a standard. Coronary calcium was measured by helical computerized tomography.
RESULTS: Two hundred patients with SLE participated. Patients had a mean age of 44.3 +/- 11.4 years and were 92% female, 61% Caucasian, 34% African American, 2% Asian, and 2% Hispanic; 18% had elevated ADMA levels. The mean ADMA was 0.31. Significantly higher ADMA levels were found in African Americans (p < 0.001), and were correlated with anti-dsDNA (p < 0.001), anti-Sm (p = 0.005), anti-ribonucleoprotein (p = 0.002), low C4 (p = 0.004), and high erythrocyte sedimentation rate (p < 0.001). ADMA was negatively associated with total cholesterol (p = 0.004). Elevated ADMA was associated with the presence of coronary calcium (p = 0.02).
CONCLUSION: Elevated ADMA is strongly associated with African American ethnicity, anti-dsDNA, low complement, and prednisone use, all markers of poor prognosis in SLE. It is negatively associated with hyperlipidemia, but positively associated with coronary calcium. Thus, it identifies a subset of SLE patients with normal lipid levels who are at risk for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611963

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Role of cardiovascular imaging in systemic autoimmune diseases.

Authors:  Simona Sitia; Luigi Gianturco; Livio Tomasoni; Maurizio Turiel
Journal:  World J Cardiol       Date:  2010-08-26

2.  Cardiovascular injury in systemic autoimmune diseases: an update.

Authors:  Maurizio Turiel; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Vito De Gennaro Colonna; Luigi Gianturco; Livio Tomasoni
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 3.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

Review 4.  Novel Surrogate Markers of Cardiovascular Risk in the Setting of Autoimmune Rheumatic Diseases: Current Data and Implications for the Future.

Authors:  Anna Mandel; Andreas Schwarting; Lorenzo Cavagna; Konstantinos Triantafyllias
Journal:  Front Med (Lausanne)       Date:  2022-06-30

Review 5.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

6.  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.

Authors:  Guillermo J Pons-Estel; Luis A González; Jie Zhang; Paula I Burgos; John D Reveille; Luis M Vilá; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-05-19       Impact factor: 7.580

7.  Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus.

Authors:  Young Hee Rho; Cecilia P Chung; Annette Oeser; Joseph Solus; Paolo Raggi; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2008-07-15       Impact factor: 4.666

8.  Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide.

Authors:  Li Zhang; Kaichong Zhang; Wei Dong; Ruizhao Li; Renwei Huang; Hong Zhang; Wanxin Shi; Shuangxin Liu; Zhuo Li; Yuanhan Chen; Zhiming Ye; Xinling Liang; Xueqing Yu
Journal:  Kidney Dis (Basel)       Date:  2020-07-28

Review 9.  Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Authors:  Theodoros Dimitroulas; Aamer Sandoo; George D Kitas
Journal:  Int J Mol Sci       Date:  2012-09-26       Impact factor: 5.923

Review 10.  Unmet medical needs in systemic lupus erythematosus.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Arthritis Res Ther       Date:  2012-12-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.